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Abstract
Background: The pharmacologic modulatory effects of the antibiotic, tunicamycin (TM), on
multidrug-resistant human UWOV2 ovarian cancer cells are reported. The UWOV2 cell line was
derived from a cystadenocarcinoma in a patient refractory to combination chemotherapy with
actinomycin D, vincristine (VCR), cis-diaminedichloroplatinum (II) (CDDP) and doxorubicin
(DXR). In an attempt to explain drug resistance in this cell line, we examined the effects of TM on
their sensitivity to various anticancer drugs, the uptake, efflux and retention of [3H]VCR, and their
ability to bind [14C]DXR and [3H]azidopine (AZD), a photoaffinity label of the multidrug
transporter, P-glycoprotein (Pgp).
Results: TM effectively decreased the EC50 for DXR, EXR, VCR and CDDP, thus enhancing their
cytotoxicity. The antibiotic also prolonged the intracellular retention time of [3H]VCR and
increased the binding of both [14C]DXR and [3H]AZD to the cells.
Conclusion:  It is concluded that the pharmacomodulatory effects of TM in these cells are
mediated by global inhibition of protein and glycoprotein synthesis and synergistic interaction with
antineoplastic drugs. The ability of TM to enhance the sensitivity of drug resistant tumour cells may
have impact on the design and optimization of novel resistance modifiers to improve the efficacy
of combination treatment of intractable neoplasms.
Background
The role of post-translational modification of proteins,
such as N-glycosylation, in normal and transformed proc-
esses is well documented [1-9]. This knowledge has
prompted explicit pharmacological interest in com-
pounds that can interfere with glycoprotein processing at
the cellular level [1,3-19]. The nucleoside antibiotic, tuni-
camycin (TM), is a prototype of substances that exert
potent inhibitory effects on protein maturation [1,2,4,20-
24]. TM has been applied, in vitro, primarily to discern the
functional significance of N-glycosylation in living sys-
tems, including cell proliferation and survival [25-28],
drug sensitivity and resistance of tumour cells to antineo-
plastic drugs [12,25,28-30], and programmed cell death
or apoptosis [21,23,27,28,31-41].
Programmed cell death is mediated through several mech-
anisms, including the endoplasmic reticulum (ER) stress
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or unfolded protein response (UPR) [35,38,41-53]. The
ER stress response typically involves transcription factor
CHOP/GADD153 (growth arrest and DNA damage 153)
and death receptor 5 (DR5) [21,23,51-54]. Perturbation
of N-glycosylation in the ER results in the expression of
aberrant or misfolded proteins which, in turn, activate the
UPR to orchestrate their decomposition and disposal by
the ER-associated protein degradation (ERAD) machinery
[55-57]. The importance of the UPR in oncogenesis and
resistance of cancers to chemotherapeutic drugs is increas-
ingly being acknowledged [19,35]. A notable corollary in
this regard is the finding that bortezomib [19,21], a
potent and selective inhibitor of the ubiquitin-proteas-
ome system (UPS, which likewise serves to identify and
remove malformed proteins [19,45,52], is also proapop-
totic – an effect triggered by TM and thapsigargin (classic
ER stress inducers) via a c-Jun-terminal kinase (JNK)-
dependent mechanism [21].
The multifactorial basis and complex nature of the molec-
ular interactions in diseases with a high prevalence [58-
60] also underscore the difficulties in predicting ovarian
tumour chemoresponsiveness and curative potential
[60,61]. The poor prognosis of ovarian carcinoma is often
ascribed to the development of multidrug resistance
(MDR) [62,63]. This lack of response to chemotherapy is
observed in many tumour types [64] and its circumven-
tion is the subject of keen research [65]. Many chemical
agents, referred to as biological response or resistance
modifiers have been demonstrated to alter chemosensitiv-
ity in refractory tumour cells and are potentially useful in
clinical cancer therapeutics [66,67]. Recently, several
efforts have been made to suppress N-glycosylation, using
TM, as a molecular tenet to overcome experimental drug
resistance [25,28-30,68]. The rationale behind this
approach is based on the assumption that inhibition of
the processing and maturation of P-glycoprotein (Pgp),
an ATP-dependent efflux pump that prevents intracellular
accumulation of cytotoxic antineoplastic drugs in tumour
cells, will necessarily alter its structural-functional integ-
rity and mediation of MDR [12,14,25,69-72].
Furthermore, there has been a renewed focus and
increased perspective on multicomponent therapeutics
for the innovation of drug discovery towards pharmaco-
logical intervention with several compounds that interact
with diverse targets [59], especially with regard to combi-
nation response reference models [58,73,74]. In this
study, we examined the pharmacomodulatory effects of
TM in the context of its interaction with the anticancer
drugs doxorubicin (DXR), epirubicin (EXR), vincristine
(VCR) and cisplatin (cis-diamine-dichloroplatinum [II],
CDDP), and the possible mechanistic relation of such
combinations to the expression of drug resistance in
human UWOV2 ovarian cancer cells. The UWOV2 cell
line was derived from a cystadenocarcinoma in a patient
refractory to combination chemotherapy with actinomy-
cin D, VCR, CDDP and DXR. Accordingly, this cell line
was taken to represent a cancer phenotype consistent with
in-vivo-acquired and/or intrinsic MDR relevant to deter-
mining the chemotherapeutic promise of modulators
used in combination with anticancer agents.
Methods
Radioisotopes, drugs and chemicals
Doxorubicin (adriamycin) and epirubicin (epidoxoru-
bicin) (Farmitalia Carlo Erba, Milan, Italy), cis-
diaminedichloroplatinum (II) (Lennon, South Africa),
gentamicin sulphate (Roussel Laboratories, South Africa),
vincristine sulphate, 3- [4,5-dimethylthiazole-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) (Sigma Chemical
Co., St. Louis, MO, USA), trypsin 1:250 (Difco Laborato-
ries, Detroit, MI, USA), PBS Dulbecco 'A' (Oxoid, UK),
RPMI-1640 and McCoy's 5A culture medium (Gibco,
UK), tunicamycin, penicillin G (Boehringer Mannheim,
Germany), EDTA (Merck Chemicals, Germany), radioac-
tive isotope precursors and drugs (Amersham Biosciences,
UK), Bio-Rad protein assay dye reagent concentrate (Bio-
Rad Laboratories, UK) were used in this study. All other
reagents were of the highest analytical grade and were
obtained from either Sigma Chemical Co. or Merck
Chemicals. P-glycoMab (consisting of lyophilized C219
monoclonal antibody and isotype-matched negative anti-
body, biotinylated anti-mouse antibody, avidin and bioti-
nylated horseradish peroxidase visualization system) was
purchased from Centocor Diagnostics, Tongeren, Bel-
gium.
Cell culture of UWOV2 cells
The UWOV2 ovarian carcinoma cell line, derived from a
cystadenocarcinoma in a patient who had not responded
to combination chemotherapy with actinomycin D, vinc-
ristine, cisplatin and doxorubicin [75], was maintained in
RPMI-1640 medium supplemented with 5% heat-inacti-
vated foetal calf serum (HIFCS), penicillin G (100 U/ml)
and streptomycin sulphate (100 µg/ml) or gentamicin
sulphate (50 µg/ml) at 37°C in 5% CO2:air and 85% rel-
ative humidity. The expression of Pgp in UWOV2 cells
was demonstrated previously using the monoclonal anti-
body, C219, and the avidin-biotin-immunoperoxidase P-
glycoCHEK diagnostic kit with the drug-sensitive human
acute lymphoblastic leukemia cell line, CCRF-CEM (Pgp-
negative) and its drug-resistant derivative, CEM-VLB100
(strongly Pgp-positive) as controls [76]. The BG-1 ovarian
carcinoma cell line and its adriamycin-resistant derivative,
BG-1/ADR were a gift from Dr C.A. Wallen (Bowman Gray
School of Medicine, North Carolina, USA) and grown in
McCoy's 5A medium containing 10% HIFCS, 100 U/ml
insulin, 200 mM L-glutamine and antibiotics. Cells were
routinely subcultured with trypsin-EDTA (0.25%–0.02%,Cancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
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w/v) in Ca+2- and Mg+2-free PBS and maintained in the
logarithmic phase of growth. Cells were periodically
tested and found to be free of mycoplasma contamina-
tion.
Precursor-incorporation-inhibition studies
The effects of TM on the incorporation of radiolabelled
precursors [35S]methionine (>1000 Ci/mmole) and
[3H]mannose (30–60 Ci/mmole) or [3H]glucosamine
(20–40 Ci/mmole) into trichloroacetic acid-insoluble
macromolecules (proteins and glycoproteins) were meas-
ured in UWOV2 cells as described previously [29].
In vitro cytotoxicity assays
To determine the effect of TM on the cytotoxicity of DXR,
EXR, VCR and CDDP, preconfluent cells from stock cul-
tures were detached with trypsin-EDTA (0.25%–0.02%,
w/v) in PBS, washed twice with PBS and resuspended in
complete culture medium to obtain single-cell suspen-
sions. Standardization of cell numbers in individual wells
of a 96-well flat-bottom microtiter plate was achieved by
a linear correlation (r = 0.98) between cell number and
absorbance up to a maximum density of 3.5–4.5 × 104
cells/well. Cells were seeded at a density of 3 × 103 cells/
well in a total volume of 200 µl as follows: After trypsini-
zation, cells were rinsed twice with PBS, resuspended in
10 ml complete culture medium and repeatedly pipetted
to ensure a homogeneous mixture during dispensing of
100-µl aliquot/well. The cells were then allowed to attach
and grow for 48–72h. Cytotoxic drugs were dissolved in
PBS and sterilized through 0.22-µm disposable filters
(Millipore, Millex-GV). The drugs were diluted in culture
medium free of phenol red (RPMI-1640-selectamine kit)
to avoid interference with spectrophotometric assays.
Tunicamycin stock solutions were prepared by dissolving
the contents of a 10-mg vial in 25 mM NaOH and then
diluting to 0.8 mg/ml TM and 10 mM NaOH with pyro-
gen-free distilled-deionized water. The solution was steri-
lized by passing through a 0.22-µm disposable filter and
diluted to final concentrations in culture medium. After
the addition of drugs and TM to octuplicate wells, cells
were incubated for a further 72h. The cytotoxicity of drug
in the TM-treated (combination) and TM-free cultures
(control) was determined by the MTT (3–4,5-dimethylth-
iazol-2,5-diphenyltetrazolium bromide) assay [77]. In
this assay, 20 µl of MTT (5 mg/ml in sterile PBS) were
added to each well and the plates incubated for 5h at
37°C. Plates were then centrifuged at 400 × g for 5 min to
pellet any floating cell aggregates. The supernatant was
aspirated and the formazan crystals dissolved in DMSO
(200  µl/well). Absorbances were read by a microplate
reader (Titertek Multiskan model MCC/340) at a sample
wavelength of 540 nm and a reference wavelength of 630
nm. The EC50 for TM, DXR, EXR, VCR and CDDP were
determined by non-linear regression of sigmoidal dose-
response curves using Graphpad Prism (Version 4.03,
GraphPad Software, San Diego California USA, http://
www.graphpad.com). The best-fit EC50  (concentration
that produces 50% of the maximal response) values for
each drug alone or in combination with a fixed concentra-
tion of 5 µg/ml TM were subjected to statistical evaluation
as described in "Data analysis".
Assay of [G-3H]vincristine sulfate uptake and efflux
To assay VCR uptake and efflux, cells were seeded at a den-
sity of 5 × 104 cells/ml in 24-well plates and allowed to
grow for 48h under standard conditions. Cells were pre-
treated with 5 µg/ml TM for 16h to suppress de novo pro-
tein and glycoprotein synthesis. Parallel controls were set
up. Total cellular accumulation of VCR was determined by
exposing cells in quadruplicate wells to [G-3H]VCR sul-
phate (30 nM or specific activity 9.48 cpm/pmol) in the
continued absence or presence of 5 µg/ml TM in a final
volume of 0.5 ml for various incubation times. At the end
of each incubation period, cells were washed three times
with 1 ml ice-cold PBS and solubilized in 0.5 ml of 1%
SDS/0.3 M NaOH. One aliquot (0.4 ml) was neutralized
by the addition of 0.2 ml of 2 M acetic acid and mixed
with 10 ml scintillation fluid (Beckman Ready-Solv EP)
and counted in a Beckman scintillation spectrometer.
Intracellular drug at each time point was determined by
subtracting the value for non-specific/surface-bound drug
obtained by incubation with 100 µM unlabelled VCR for
30s at 4°C from the value for total drug. The other aliquot
(0.1 ml) was assayed for total cellular protein. Vincristine
efflux was measured by loading control and TM-pre-
treated cells with [3H]VCR for 60 min (0-time value for
efflux) followed by washing preloaded cells three times
with ice-cold PBS and subsequently incubating at 37°C in
serum- and antibiotic-free medium (2 ml) for various
time intervals. The absence or presence of TM was main-
tained throughout the post-incubation periods. Cells were
harvested as described for uptake studies. A large volume
ratio (i.e., preloading volume/post-incubation volume of
4) was ensured during efflux and retention measurements
to minimize reutilization of extruded drug.
Binding of [3H]azidopine and [14C]doxorubicin to UWOV2 
cells
The specific binding of [3H]AZD (46 Ci/mmol) and
[14C]DXR (50–62 mCi/mmol) to UWOV2 cells in the
absence (control) or presence of TM (TM-treated) was
measured by a modification of the procedure described
earlier [78]. Cells were seeded at a density of 5 × 104 cells/
ml in 24-well plates. Confluent cell monolayers were
cooled by placing the plates on ice for 10 min, washed
four times with 1 ml cold PBS, pH 7.4 (to remove culture
medium serum glycoproteins) and maintained for 60 min
at 4°C with binding buffer (10 mM glucose, 3 mM ATP
and 5 mM MgCl2 in 10 mM Tris-HCl, pH 7.4) containingCancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
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[3H]AZD or [14C]DXR in serial dilutions of 10–80 nM.
Following this incubation period, the cells were washed
five times with cold PBS to remove unbound [3H]AZD
and [14C]DXR. Cells were then solubilized in 0.1 M NaOH
and samples were counted to determine the amount of
AZD or DXR bound to the cells, and aliquots were
removed for protein determination. Specific binding was
distinguished from non-specific binding to cells and plas-
tic wells by dilution with excess (100 µM) unlabelled
drug. To examine competitive binding between DXR and
AZD, cells were exposed to equimolar concentrations of
both compounds (unlabelled DXR and labelled AZD) and
the specific binding of AZD determined as described
above. The specific activity of the UWOV2 cell surfaces/
receptors (Bmax) and the binding affinity constant (Kd) for
DXR and AZD were determined by non-linear regression
(one-site binding hyperbola) of specific binding data,
using GraphPad Prism http://www.graphpad.com.
Protein determination
The total cellular protein content was estimated by utiliz-
ing the Bio-Rad protein dye-binding assay kit.
Data analysis
Statistical analysis was performed on the variables in this
study using either the Student's two-tailed t-test or one-
way ANOVA. The level of significance was set at p < 0.05.
Values are representative of the means ± SEM of 3 experi-
ments (n = 8 for each experiment), unless indicated oth-
erwise. Actual p values are presented. An experimental
design for comparison of a single anticancer drug dose-
response relation with that of the same anticancer drug in
combination with a fixed concentration of 5 µg/ml TM
was used and the measured responses compared to both
the Loewe additivity and Bliss independence reference
models of synergy [73,79,80] using the CombiTool com-
puter programme (version 2.001, IMB Jena Biocomputing
Group, http://www.imb-jena.de). The drug interaction
index (Ix) was calculated according to the method of Chou
and Talalay [81] using CombiTool. Ix values are geometric
means ± SEM (standard error of the mean) of multiple
effect levels (fraction affected, Fa) 0.1, 0.2, 0.3,..., 0.99
(i.e., EC10, EC20, EC30,..., EC99) for each drug in the dose
range 10-4 to 101 µg/ml in the presence of a fixed concen-
tration of 5 µg/ml TM: Ix < 1 ⇒ synergy; Ix = 1 ⇒ additivity
and Ix>1 ⇒ antagonism. The Loewe dose additivity model
is defined by the equation dx/Dx + dy/Dy = 1, where Dx
and Dy represent the concentrations of individual drugs
required to exert the same effect as concentrations dx and
dy used in combination. In this case, dx would be the
effective inhibitory concentration (EC) of the drug used in
combination with TM and Dx the EC of the drug alone.
Likewise, dy would be the fixed concentration of TM used
in combination with the drug and Dy the EC of TM (deter-
mined from the individual dose-response relation for TM)
to produce the same effect. Student t-tests were performed
to evaluate significant differences in Ix compared to a null
hypothesized Ix value of 1. The Bliss independence model
is defined by the equation: Exy = Ex + Ey - ExEy for 0 < E < 1
and where Exy is the additive effect of drugs x and y as pre-
dicted by their individual effects Ex and Ey. In this case, Exy
would be the effect (fractional survival) of the drug used
in combination with TM, and Ex and Ey the fractional sur-
vival of cells exposed to the drug alone and to the drug in
combination with TM, respectively. EC50 data are best-fit
values obtained from non-linear regression analysis of the
sigmoidal dose-response relation for each drug alone or in
combination with TM. The potency ratio and associated
95% CI (confidence interval) were computed according to
the method of Fieller [82] by subtracting the log EC50 of
drug in combination with TM from the log EC50 of drug
alone and back-transformation (antilogarithm) of data.
GraphPad QuickCalcs, Graphpad Prism (Version 4.03,
GraphPad Software, San Diego California USA, http://
www.graphpad.com), SigmaPlot (version 9.01) and Sig-
maStat (Version 3.11) (Systat Software, Inc. 501 Canal
Blvd, Suite E, Point Richmond, CA 94804-2028, USA,
http://www.systat.com) were used for data and graphic
analysis.
Results
Precursor-incorporation-inhibition studies
The inhibitory effects of TM on UWOV2 cells were meas-
ured by following the incorporation of radiolabelled pre-
cursors into proteins and glycoproteins. In the presence of
TM, a marked inhibition of protein (Figure 1A) [see Addi-
tional file 1] and glycoprotein (Figure 1B) [see Additional
file 1] synthesis was observed in UWOV2 cells. The incor-
poration of [35S]methionine into cellular protein was
greatly diminished at all incubation times, except at 4h
(Figure 1A) [see Additional file 1]. The concentration-
dependent effect of TM on [3H]glucosamine incorpora-
tion by UWOV2 cells is shown in Figure 1B [see Addi-
tional file 1]. At concentrations less than 0.05 µg/ml, TM
had no inhibitory activity, but at higher concentrations
(0.5–50 µg/ml) the antibiotic significantly impaired glyc-
oprotein synthesis compared to control. The inhibitory
effect of TM was verified by similar analysis of the incor-
poration of [3H]mannose into glycoprotein in the absence
(control) or presence of 5 µg/ml TM (TM-treated) at dif-
ferent time intervals following an initial 16h pre-incuba-
tion with the antibiotic (Figure 2) [see Additional file 2].
In vitro cytotoxicity assays
The effects of TM on the viability of UWOV2 cells are
depicted in Figure 3 [see Additional file 3]. TM did not
affect cell viability in the concentration range 0.0001–5
µg/ml and survival was consistently greater than 95% or
similar to control (i.e., cells not treated with TM). The
best-fit estimate of the EC50 for TM in UWOV2 cells wasCancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
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23.6 µg/ml (95% CI: 10.34 to 53.96), compared to a ref-
erence ovarian cancer cell line BG-1 (EC50, TM = 16.81 µg/
ml; 95% CI: 5.87 to 48.17) and its adriamycin (DXR)-
resistant variant, BG-1/ADR (EC50, TM = 64.84 µg/ml;
95% CI: 18.98 to 221) (survival curves of TM for BG-1 and
BG-1/ADR are not shown). Dose-response curves for
UWOV2 cells treated with different drugs alone or in com-
bination with 5 µg/ml TM are presented in Figure 3 [see
Additional file 3] and the results obtained from non-lin-
ear regression of the sigmoidal dose-response relation for
each drug alone or in combination with TM are summa-
rized in Table 1 [see Additional file 4]. The cells displayed
a high degree of resistance to VCR (EC50 = 23.2 µg/ml;
95% CI: 9.11 to 59.07) relative to the other drugs: 5.86-
fold > DXR (95% CI: 2.46 to 14), 8-fold > EXR (95% CI:
1.86 to 35.17) and 5.67-fold > CDDP (95% CI: 2.43 to
13.35). One-way ANOVA revealed no major variations in
the log EC50 of DXR and EXR (p = 0.711), DXR and CDDP
(p = 0.971) as well as EXR and CDDP (p = 0.684), but sig-
nificant differences between the log EC50 of DXR and VCR
(p = 0.041), EXR and VCR (p = 0.016), and CDDP and
VCR (p = 0.044). TM potentiated the cytotoxicity of all the
drugs by effectively decreasing their EC50 and, correspond-
ingly, increasing the potency ratio for each drug in the fol-
lowing order of magnitude: EXR (102-fold) > DXR (88-
fold) > CDDP (17-fold) > VCR (5-fold) (Table 1).
Unpaired t-tests for the differences in log EC50 for drug
alone and drug in combination with TM yielded p values
less than 0.001 for DXR, EXR and CDDP, but not for VCR
(p = 0.335). Thus, although TM increased the potency
ratio for VCR in UWOV2 cells, the enhanced toxicity was
not statistically significant.
Drug synergy analysis
The influence of TM on the efficacy of the anticancer drugs
under study was further appraised in respect to the differ-
ences of the measured responses and the expected values
generated from the CombiTool programme for the Loewe
additivity and Bliss independence models for drug inter-
action (Figure 4) [see Additional file 5]. Loewe and Bliss
antagonism were observed at the lower range (lower effect
levels) of drug concentrations (0.0001 to 0.003 µg/ml) for
DXR and CDDP and at 0.0001 for VCR (not shown),
whereas all the drugs in combination with TM displayed
Loewe and Bliss synergism at higher effect levels (Figures
4A and 4B, respectively) [see Additional file 5]. The syner-
gistic action between TM and the different anticancer
drugs was confirmed by the generalized isobolar median-
effect method, using the CombiTool computer pro-
gramme. The results, presented in Figure 4C [see Addi-
tional file 5], show that synergism occurs at effect levels
(fraction affected, Fa) of 0.2 and above. The combination
index (Ix) for each drug at multiple effect levels was also
compared with a null hypothesized value of 1 and yielded
p values < 0.001 in all cases, thus indicating a high degree
of synergism, according to the Loewe additivity model, for
all the TM-drug combinations (Table 1).
Assay of vincristine uptake and efflux
Based on the relatively high degree of resistance of
UWOV2 cells to VCR and the synergistic action of TM on
its potency, an investigation into the direct effects which
TM might exert on the transport of VCR in these cells was
undertaken. This, along with the assumption that VCR
transport in these cells is coupled to the expression of Pgp,
therefore provided an approach that could reflect a gen-
eral association between inhibition of protein and glyco-
protein synthesis and the drug transport mechanism. The
effects of TM on the transport of [G-3H]VCR into (uptake)
and out of (efflux) UWOV2 cells are shown in Figure 5
[see Additional file 6]. TM had no appreciable effect on
the saturable uptake of VCR by these cells (Figure 5A) [see
Additional file 6], but VCR efflux was significantly and
consistently inhibited at post-incubation times 60 min (p
< 0.001), 120 min (p = 0.004) and 180 min (p = 0.004)
(Figure 5B) [see Additional file 6]. Data obtained for sep-
arate experiments which emulated efflux studies, on the
retention of VCR in response to TM treatment, are sum-
marized in Figure 6 [see Additional file 7]. TM induced a
consistent 20% increase in the fractional retention of VCR
in UWOV2 cells at post-incubation times 60 min (p =
0.004), 80 min (p = 0.029) and 100 min (p = 0.027). The
results show that by lowering the efflux rate of VCR from
the cells, probably via inhibition of Pgp synthesis and
function, TM concomitantly raises the amount of drug
retained in the cells. Such increased retention of VCR
brought about by TM may well explain the observed
increased efficacy or potency of VCR and the other drugs
when combined with TM, especially in view of the molec-
ular components targeted in the experimental setup.
Therefore, overall inhibition of both protein and glyco-
protein synthesis as well as drug efflux which possibly
involve Pgp in the interconnected system may account for
the observed enhancing effects of TM on drug cytotoxicity
in UWOV2 cells.
Binding of azidopine and doxorubicin to UWOV2 cells
The MDR status of UWOV2 ovarian carcinoma cells was
demonstrated, in part, by measuring the specific binding
of [3H]AZD, a photoactive dihydropyridine calcium chan-
nel blocker known to bind to Pgp, and [14C]DXR to intact
cells in culture at 4°C in the absence (control) or presence
of 5 µg/ml TM (TM-treated) following an initial 16h pre-
incubation at 37°C with or without the antibiotic. The
binding of DXR to the cells was saturable in the linear con-
centration range of 0–80 nM (Figure 7A) [see Additional
file 8]. The measured binding affinity for DXR in control
cultures was Kd = 28.48 ± 14.94 nM (95% CI: 0–59.5) and
the receptor/cell surface specific activity was Bmax = 0.61 ±
0.14 pmol/mg (95 % CI: 0.33 to 0.89). In the presence ofCancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
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TM, the Bmax for DXR was increased 2.87-fold (95 % CI:
1.05 to 7.33, p = 0.045) as determined by Fieller's ratio of
means test. The unpaired t-test for the difference in Kd for
control and that for TM-treated cells (Kd = 60.82 ± 26.66
nM (95 % CI: 5.52 to 116) indicated no significant change
in this parameter for DXR (p = 0.331). Taken together, the
results show that the increased binding of DXR to
UWOV2 cells in the presence of TM is probably caused by
a mechanism which facilitates DXR attachment to the
cells. This supposition was corroborated by an analysis of
the results in terms of fractional occupancy of binding
sites as predicted by the law of mass action at equilibrium
(saturation), i.e., a plot of fractional occupancy ([DXR]/
([DXR] + Kd) vs [DXR]/Kd yielded a rectangular hyperbola
(not shown) similar to Figure 7A [see Additional file 8].
The plot revealed that maximal occupancy of DXR bind-
ing sites was attained at much lower concentrations of
DXR when cells had been treated with TM. Although the
precise molecular mechanism has yet to be established, it
is apparent that TM pre-treatment facilitates DXR binding
on UWOV2 cell surfaces. The binding of the photoaffinity
label of Pgp, [3H]AZD, to intact cells (control) and cells
treated with TM was studied as described for DXR. Bind-
ing of AZD remained linear (i.e., non-saturation binding)
between 0 and 80 nM (Figure 7B) [see Additional file 8].
TM treatment also significantly increased the binding of
AZD to cells at all the concentrations studied (p = 0.008).
In the presence of equimolar concentrations (range 30–80
nM) of unlabelled DXR, the binding of labelled AZD to
UWOV2 cells was significantly reduced (Figure 7B, p <
0.005) [see Additional file 8], suggesting interaction of
DXR with Pgp. This reduction of AZD binding to UWOV2
cells in the presence of DXR was attenuated by treatment
of cells with TM (Figure 7B, p < 0.005) [see Additional file
8]. Non-linear regression analysis of AZD binding did not
converge and could not be performed as the incubation
was in the linear region, i.e., saturation (equilibrium) was
not reached. This could well have been accomplished in a
study design with log increments of AZD concentration,
but was not considered crucial for the purpose of this
investigation.
Discussion
Effective management of ovarian carcinomas is often lim-
ited by their relative lack of response to chemotherapy.
Ovarian tumours have been reported to manifest the
MDR phenotype variously [61-63,70,83]. In addition, the
development of resistance to drugs that are most active
against ovarian cancer may occur through mechanisms
other than the expression of Pgp [84,85]. Despite this and
the large variability in Pgp levels observed in ovarian can-
cer [70,83,86], the insensitivity of this malignancy to
chemotherapy can be correlated with the expression of the
mdr1 gene product [61,87-89]. We have previously dem-
onstrated the expression of Pgp in UWOV2 cells using the
P-glycoCHEK immunocytochemical diagnostic kit and
verified its presence in these cells with SDS-PAGE of puri-
fied plasma membrane samples immunoprecipitated
with Pgp-specific mAbs MRK-16 and C219 [76]. Ovarian
carcinoma cell lines, such as UWOV2, derived from clini-
cally drug-resistant patients, are useful for in vitro antican-
cer drug screening and the identification of valuable novel
treatment regimens [88,90].
In our system, the inhibition of de novo synthesis of pro-
teins and glycoproteins can be explained by the potent
suppression by TM of [35S]methionine, [3H]mannose and
[3H]glucosamine incorporation into UWOV2 cells. A
model for such TM-mediated translational inhibition
(i.e., attenuation of the transfer of oligosaccharide units to
specific asparaginyl (Asn) residues in nascent polypep-
tides within the lumen of the ER to form N-linked glyco-
proteins) illustrates why an inadequate supply of the
lipid-linked oligosaccharide Glc3Man9GlcNAc2-P-P-doli-
chol precursor may block the maturation of glycoproteins
and their translocation to membranes [91]. Agents that
perturb N-glycosylation and protein folding in the ER
induce the UPR response and eventually growth arrest or
apoptosis if the homeostatic compensatory mechanisms
are insufficient to cope with unabated ER stress
[42,51,52].
Cellular insults by inducers of ER stress such as TM and
thapsigargin, activate the ubiquitin-proteasome system
(UPS), a catalytic proteinase complex which neutralizes
proteins with abnormal conformations [19,45,52]. Treat-
ment of MDR cells with an inhibitor of N-glycosylation
increases ubiquitinylation of Pgp [72]. Ubiquitinylation is
a recognized signal for the upregulation of protein degra-
dation and a process that would affect the stability and
function of Pgp. Inhibition of N-linked glycosylation by
TM has also been associated with enhanced turnover of
misfolded proteins which is carried out by the UPS
[41,92]. The precursor form of Pgp is non-glycosylated
with apparent molecular mass (MWapp) varying between
120 to 140 kDa [12]. Also, reduction in the MW of Pgp
from 180 kDa to 150 kDa, upon exposure of cells to TM,
is well established [68]. Correspondingly, Pgp has been
reported to be differentially glycosylated resulting in het-
erogeneous forms of MDR-associated glycoproteins in dif-
ferent cell lines which may or may not correlate with drug
resistance [93].
Since N-linked glycosylation occurs in the ER, TM as an
inducer of the UPR may affect the proper folding of Pgp
and prevent its insertion into the plasma membrane thus
altering membrane topology and permeability [68]. How-
ever, a recent report asserted that Pgp-mediated vinblast-
ine efflux in rat hepatoma cells was increased despite
impaired glycosylation and induction of the ER stressCancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
Page 7 of 11
(page number not for citation purposes)
response by TM, 2-deoxyglucose and thapsigargin [69].
Thapsigargin and TM, agents that induce ER stress, have
been shown to sensitize breast (MCF-7) and prostate
(DU145) cancer cells to the cytotoxic effects of diindolyl-
methane (DIM), raising the possibility that stressed cells
also have increased sensitivity to cytotoxic agents [23].
Evidence in support of such a notion has been provided
by a study in which the combined exposure of myeloma
cells to the proteasome inhibitor MG-132 and the ER
stressor TM resulted in a synergistic cytocidal effect [94].
Similarly, bortezomib – another proteasome inhibitor
with substantial antitumour efficacy [19,21] – markedly
improved the sensitivity of pancreatic cancer cells to cispl-
atin and further promoted apoptosis induced by TM and
thapsigargin [21]. Moreover, the establishment of a func-
tional link between N-glycosylation and apoptosis
[31,40,41] and the observation that CDDP-resistance in
an ovarian carcinoma is coupled with a defect in pro-
grammed cell death [95] is interesting. Therefore, deline-
ation of the tangible effects of TM on the ER signalling
pathway in relation to tumour cell death may offer pros-
pects for rational anticancer drug design and more effec-
tive chemotherapeutic combinations
[20,21,23,48,54,69,96].
The increased binding of DXR and AZD, in particular, to
intact UWOV2 cells in the presence of TM implies that the
antibiotic may exert its effects by modulating cell surface
binding activity either through direct membrane pertur-
bations and/or alterations in the integrity of Pgp [97].
Such effects may ultimately be responsible for changes in
Pgp-substrate, -ligand and -inhibitor absorption, distribu-
tion and excretion [98]. Structural analysis of these inter-
actions would bolster our understanding of the precise
relationship between the signature effects of TM and Pgp-
mediated drug binding and efflux [71].
In this study, a modulatory influence of TM on the
responses of UWOV2 cells to commonly used anticancer
drugs was noted by the significant decreases in EC50 of
these drugs when used in combination with the antibi-
otic. The observed inhibition of VCR efflux from and its
increased intracellular retention in UWOV2 cells follow-
ing treatment with TM is in agreement with assertions that
Pgp becomes inactive when its maturation, i.e., post-
translational modification (N-glycosylation) is inhibited
[25,28,30,99]. Hence, by blocking active efflux of the
drug, TM may enhance chemosensitivity in terms of drug
efficacy (potency) by increasing the net intracellular avail-
ability of the drug to wield its cytotoxic charge. Several
studies suggest that the down-regulation of drug efflux
may prove beneficial in overcoming drug resistance
[29,98,100-103]. Lack of agreement on this posit may be
explained by the fact that MDR is a multifactorial phe-
nomenon in which the expression of alternative biochem-
ical pathways related to defence and detoxification
mechanisms, alterations in drug-target interactions and
cellular responses to DNA damage are interlinked, yet
phenotype-specific. By analogy, the molecular complexi-
ties in the systems studied and the diverse effects of TM at
the cellular level may also account for conflicting observa-
tions.
This study has demonstrated that TM significantly
increases the toxicity of various anticancer drugs in
UWOV2 ovarian cystadenocarcinoma cells. The conform-
ity of the data to the quantitative index of drug combina-
tion (Ix) suggests that when TM is used conjointly with
anticancer drugs, their efficacy is greatly enhanced
through synergistic interaction, consistent with both the
Loewe additivity and Bliss independence models
[73,79,80]. The results have definite applications in
research on refractory tumours, judging by the current
gravity of the concept of synergy from the perspective of
augmented drug potency and the promise it holds for
drug discovery, development and optimization of adju-
vant combinations [58,74]. The effects of TM in our exper-
imental system were achieved through overall
perturbation of the synthesis and function of proteins and
glycoproteins. In this regard, Pgp, by virtue of its expres-
sion on UWOV2 cell surfaces and as one of the most likely
causative molecules mediating ovarian tumour non-
responsiveness, is not exempt from such targeting. Thus,
the modulatory and inhibitory effects of TM on the doli-
chol-N-glycosylation pathway may be exploited in vitro as
a useful strategy to interfere with the de novo formation of
Pgp in order to render cells hypersensitive to anticancer
agents. The relationship between drug synergism and
mechanism is increasingly being recognized as an impor-
tant consideration in multitherapeutic clinical rationales
that would offer superior efficacy and lesser toxicity
[58,74].
This study sought to address the broad mechanistic
aspects underlying the observed synergistic responses of
UWOV2 cells to TM-drug combinations. Further studies
using immunohistochemical or flow-cytometry tech-
niques are needed to profile the effect of TM on the
expression levels of different drug efflux pumps in the
UWOV2 cell line. The effect of TM described here may not
be specific to ABC transporters, but rather universal. This
opens new avenues to differentiate the TM-mediated
effect between cancer cells and normal cells and, in partic-
ular, how such cellular sensitivities correlate with biomar-
kers for MDR [4]. The clinical application of TM, however,
must await careful investigations relating to its in vivo tox-
icity.Cancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
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Additional material
Additional file 1
Figure 1. Effects of tunicamycin (TM) on protein synthesis (A) and glyc-
oprotein synthesis (B) in UWOV2 ovarian carcinoma cells in culture. 
Protein synthesis was monitored by measuring the incorporation of 
[35S]methionine into cellular protein at various time intervals in the 
absence (control) or presence (TM-treated) of the antibiotic. Glycoprotein 
synthesis as a function of TM concentration was evaluated by determining 
the amount of [3H]glucosamine incorporated into cellular protein after 
16h of exposure to the antibiotic. Data represent means ± SEM (n = 4). 
Two-tailed p values for the difference between control and TM-treated 
cells are presented within bars.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S1.doc]
Additional file 2
Figure 2. Effect of tunicamycin (5 µg/ml) on the incorporation of 
[3H]mannose by UWOV2 ovarian carcinoma cells in culture and the cor-
responding level of inhibition of mannosylglycoprotein synthesis. Values 
are means ± SEM (n = 4).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S2.doc]
Additional file 3
Figure 3. The effects of TM on drug cytotoxicity in UWOV2 ovarian car-
cinoma cells. Cells were seeded at a density of 3 × 103 cells/well in octu-
plicate wells and allowed to attach and grow for 48–72h. Cells were were 
exposed to TM, drug, or to drug in combination with a fixed concentration 
of 5 µg/ml TM for a further 72h after which cell survival was determined 
by the MTT assay. A, DXR; B, EXR; C, VCR; D, CDDP. Data points are 
connected by non-linear regression lines of the sigmoidal dose-response 
relation. Values are means ± SEM for 3 experiments (n = 8 for each exper-
iment).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S3.doc]
Additional file 4
Table 1 (Must form part of the main document). Table 1. Tunicamy-
cin-induced sensitization of UWOV2 ovarian carcinoma cells to various 
antineoplastic drugs
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S4.doc]
Additional file 5
Figure 4. Synergy analysis of the different antineoplastic drug and TM 
combinations in UWOV2 ovarian carcinoma cells. The median-effect 
function of Chou and Talalay, assuming mutual exclusivity, using the 
CombiTool (version 2.001) was applied to analyze both the Loewe addi-
tivity (A) and Bliss independence (B) reference models. A quantitative 
measure of drug interactions is provided by the interaction index of the iso-
bologram equation (C). Plots show the different combination indices at 
various effect levels (fraction affected) for an experimental design in 
which the doses of the respective antineoplastic drugs were varied in the 
presence of a fixed dose of TM. The dashed line indicates the Loewe addi-
tivity hypothesis, i.e. interaction indices greater than 1 were antagonistic 
and those less than l were synergistic. Values are means for 3 experiments 
(n = 8 for each experiment). The coefficient of variation for each set of 
experiments was < 10%.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S5.doc]
Additional file 6
Figure 5. Time course of VCR uptake (A) and efflux (B) in human 
UWOV2 ovarian carcinoma cells. To assay VCR uptake and efflux, cells 
were pretreated for 16h with 5 µg/ml TM. Parallel controls were set up. 
Total cellular accumulation of [G-3H]VCR was determined at the end of 
each incubation period as described in Materials and methods. Efflux was 
measured by loading control and TM-pretreated cells with [G-3H]VCR for 
60 min (0-time value for efflux) followed by washing preloaded cells three 
times with ice-cold PBS and subsequently incubating at 37°C in serum- 
and antibiotic-free medium for various time intervals. The absence or pres-
ence of TM was maintained throughout the post-incubation periods. Cells 
were harvested as described for uptake studies. Values are means ± SEM 
(n = 4) of 3 experiments. Student's two-tailed p values for the difference 
between control and TM-treated cells for the different time points are 
shown on top of panels.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S6.doc]
Additional file 7
Figure 6. Effects of tunicamycin on the retention of vincristine in drug-
resistant UWOV2 human ovarian carcinoma cells at different time inter-
vals after a 1-hr pre-loading period with the drug and subsequent exposure 
to drug-free medium. Values are means ± SEM (n = 4). Student's two-
tailed p values for the difference between control and TM-treated cells are 
presented within bars.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S7.doc]
Additional file 8
Figure 7. Specific binding of [14C]DXR (A) and [3H]AZD (B) to cul-
tured UWOV2 cells at 4°C for 60 min in the absence (control) or pres-
ence (TM-treated) of 5 µg/ml TM following an initial 16-h pre-
incubation at 37°C with or without TM. Specific binding of DXR and 
AZD was calculated by subtracting non-specific binding data obtained in 
the presence of 100 µM each of unlabelled DXR and AZD, respectively, 
from total binding. Each point represents the mean ± SEM (n = 4). 
Upaired t-test results for the difference between control and TM-treated: 
p = 0.018 (10 nM 14C-DXR), p = 0.005 (20 nM 14C-DXR); p = 0.002 
(40 -80 nM 14C-DXR), p ≤ 0.008 (10, 20, 40 and 80 nM 3H-AZD), p 
< 0.0001 (30 nM 3H-AZD), p = 0.012 (80 nM 3H-AZD, for difference 
between Equimolar DXR vs Equimolar DXR + TM).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1475-
2867-7-5-S8.doc]Cancer Cell International 2007, 7:5 http://www.cancerci.com/content/7/1/5
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